The manager will succeed Stephan Sturm at the helm of Fresenius from October.
(Photo: Fresenius)
Dusseldorf, Munich, Frankfurt This change was in the air: At the beginning of October, Michael Sen will become the new CEO of the Fresenius healthcare group. The head of the drug subsidiary Kabi will replace Stephan Sturm and should initiate the turnaround at the Dax group.
The chairman of the board, Sturm, who has been in office since 2016, recently acted unhappily. After several profit warnings, the 59-year-old had lost confidence – not only among investors, but also with the supervisory board, which decided to replace him on Friday.
Now Michael Sen should go. The appointment of the 53-year-old should give Fresenius shares a boost, which had lost more than 60 percent in value since Sturm took office in mid-2017. On Friday evening, the papers were already up after the trading hours.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue